# Exai oncRNA prospective study by cancer size and stage

Source: https://onco.cc/trials/exai-oncrna-prospective/  
OnCo record `exai-oncrna-prospective` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exai Bio's study of a blood test that looks for small RNA molecules made by tumours.

## Summary

Exai oncRNA prospective study by cancer size and stage (NCT05833360) is an observational study sponsored by Exai Bio Inc. It develops and evaluates the Exai oncRNA blood test for cancer detection, stratified by tumour size and stage.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,400 participants, a start on 14 July 2023 and primary completion expected on 14 July 2030.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Registry id: NCT05833360
- Phase: observational
- Setting: People with and without cancer at US sites, testing a blood test based on orphan non-coding RNAs
- Sponsor: Exai Bio Inc.
- Enrolled: 2400

## Sources

- ClinicalTrials.gov NCT05833360: https://clinicaltrials.gov/study/NCT05833360

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- companies: [Exai Bio](https://onco.cc/companies/exai-bio/)

---
JSON: https://onco.cc/api/v1/entities/exai-oncrna-prospective.json